Not exact matches
Immune
cells modified by CRISPR - Cas9 were inserted into a
lung cancer patient at the West China Hospital
in Chengdu
in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered
cells in order to assess the method's safety.
The medicines, which help unleash the immune system on
cancer cells, were tested
in patients with advanced
lung cancer.
Researchers from the Sichuan University
in Chengdu inserted the re-engineered
cells into a
lung cancer patient participating
in a clinical trial at the West China Hospital on October 28th, according to Nature.
The PD - 1 checkpoint inhibitor Keytruda hit its goals
in a new trial
in previously untreated non-small
cell lung cancer patients, beating chemo at staving off
cancer progression and extending
patients» lives.
April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone
in newly - diagnosed
patients with advanced non-small
cell lung cancer in a highly - anticipated study that appears to cement the company's lead
in the most lucrative oncology market.
They'll also jointly market Pfizer's drug Xalkori, which is approved
in more than 75 countries for treating non-small
cell lung cancer in patients with a certain genetic mutation.
The biotech specialist said that its updated phase 2 data
in a study of its poziotinib candidate treatment for non-small
cell lung cancer resulted
in a preliminary confirmed objective response rate and potential progression - free survival benefit
in patients with the EGFR Exon 20 Mutant form of the disease.
In a mid-stage trial, 16 of 37
lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood
cell counts.
«We feel it'll be able to help kill
cancer cells in 80 percent of breast
cancer patients,» said Dr. Olson, who added that their antibody has the potential to help kill
lung, colon, prostate and other
cancer cells, too.
There is currently a PD - 1 antibody on the market that blocks T
cell exhaustion
in patients with solid tumors, like
lung cancer and melanoma.
One,
in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small
cell lung cancer (SCLC)
patients who received statins.
Among
patients who have this type of
lung cancer, nearly one
in three will carry a particular genetic mutation on their
cancer cells.
They found out that TiY is capable of distinguishing TICs from non-TICs
in various human
lung cancer cell lines and
patient - derived
lung tumors.
However, the Moffitt scientists suggest that it may be possible to target the TGF - β - miR183 - DAP12 pathway
in patients with
lung cancer to activate the immune system and kill
cancer cells.
A drug approved by the Food and Drug Administration (FDA) for melanoma
in combination with a common cholesterol - lowering drug may show promise
in controlling
cancer growth
in patients with non-small
cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.
Among
patients with non-small
cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease
in the number of circulating tumor
cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.
«FDG PET shows tumor DNA levels
in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for
patients with advanced non-small
cell lung cancer.»
Italian researches have demonstrated a better way of determining the aggressiveness of tumors
in patients with advanced non-small
cell lung cancer (NSCLC).
One successful compound, named Exel 647, that targets nonsmall -
cell lung cancer in previously untreated
patients is now
in a phase 2 clinical trial.
Some
patients with non-small
cell lung cancer (NSCLC) have changes
in the anaplastic lymphoma kinase (ALK) gene, which can drive the development of their
cancer.
Among
patients with advanced non-small
cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement
in survival without progression of the
cancer, but not with overall survival, according to a study
in the April 9 issue of JAMA.
Around 1,600 people are diagnosed with non-small
cell lung cancer in Greater Manchester every year and a proportion of these
patients will have the ALK - positive type.
Epidermal growth factor receptor (EGFR) mutations found
in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small
cell lung cancer (NSCLC)
patients correlates well with the EGFR mutations from
patient - matched tumor tissue DNA.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for
patients with advanced non-small
cell lung cancer (NSCLC) who have mutations
in the EGFR gene.
«If you look at a set of
lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
cancer patients, like we did
in the paper, who develop brain metastases, they all have those two genes
in their primary
lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem
Cell and
Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.
In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodie
In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy
in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodie
in 541
patients with previously untreated or recurrent non-small
cell lung cancer (NSCLC) that expressed PDL - 1 antibodies.
«We now know much more about metabolic reprogramming of cancerous tissues
in human
patients, particularly that the activation of pyruvate carboxylase is important to
lung cancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of Ken
cancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey
Cancer Center and CESB at the University of Ken
Cancer Center and CESB at the University of Kentucky.
The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants
in Non-Small
Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patie
Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat pat
Cancer,» and published online
in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found
in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patie
lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat pat
cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat
patients.
Examination of gene expression
in patients with non-small
cell lung cancer (NSCLC) showed the area adjacent to tumors is rich with
cancer markers.
The
cells exhibited many functions associated with tumor progression; their presence within mouse tumors substantially accelerated
cancer growth, and
in human
lung tumors, a SiglecFhigh neutrophil signature was associated with poor
patient survival.
In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therap
In a letter published
in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therap
in the
cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP
in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therap
in Paris, France, report that while treating an HIV - infected
lung cancer patient with the
cancer drug nivolumab, they observed a «drastic and persistent decrease»
in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therap
in the reservoirs of
cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therap
in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.
In September oncologists reported they sequenced deadly squamous cell lung cancer in 178 patient
In September oncologists reported they sequenced deadly squamous
cell lung cancer in 178 patient
in 178
patients.
A new drug that targets not only common
cancer - causing genetic mutations
in patients with non-small
cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results
in patients in a phase I / II clinical trial.
To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a
cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-
cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for
Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-
Cancer Immunotherapy studied tumors of four
patients with non-small
cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-
cancer and one
patient with head and neck
cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-
cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or
in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.
Among
lung cancer patients; suicide SMR was higher
in males (SMR = 8.8), Asians (SMR = 13.7), widowed
patients (SMR = 11.6), older
patients (70 - 75 years; SMR = 12),
patients with undifferentiated tumors (SMR 8.6) or small
cell lung carcinoma (SCLC) histology (SMR = 11.2),
patients presenting with metastatic disease (SMR = 13.9) and
in patients who refused to receive surgical treatment (SMR = 13).
It doesn't kill the
cell that it hides
in, but is dangerous enough that it can cause infections
in individuals with an impaired immune system, such as
patients who are receiving
cancer treatment, who have pre-existing
lung problems or whose immune systems are otherwise compromised.
«Our laboratory results are promising and certainly provide encouragement to test this treatment clinically
in patients with small
cell lung cancer.»
Researchers enrolled 102
patients in with advanced non-small
cell lung cancer in the phase 1b study to evaluate the durvalumab and tremelimumab combination therapy.
«Faris and colleagues intend to evaluate all
patients with suspected or confirmed non-small
cell lung cancer in the future — a point that deserves emphasis,» said Dr. Farjah.
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival
in patients with non-squamous non-small
cell lung cancer (NSNSCLC) lacking genetic changes
in the EGFR or ALK genes, when compared to...
Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen Y - T, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Vaccine - induced CD4 + T
cell responses to MAGE - 3 protein
in lung cancer patients.
ARandomized, Phase III, Double - Blind Placebo - Controlled Trial of Sunitinib as Maintenance Therapy
in Non-Progressing
Patients following an Initial Four Cycles of Platinum - Based Combination Chemotherapy
in Advanced, Stage IIIB / IV Non-Small
Cell Lung Cancer
A Phase 2 Study of MM - 121
in Combination with Docetaxel versus Docetaxel Alone
in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small
Cell Lung Cancer
The purpose of this study is to compare the effectiveness of daratumumab
in combination with atezolizumab against atezolizumab alone
in patients who have advanced non-small
cell lung cancer (NSCLC) that has previously been treated.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236
patients with various types of
cancer, the treatment shrank tumors
in 28 percent of melanoma
patients, 30 percent of
patients with kidney
cancer, and 18 percent of
patients with advanced non-small
cell lung cancer.
$ 1.8 M Supports
Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem
Cell Transplant
Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways
in the Development of Ovarian
Cancer GMNews.com - March 2, 2016 Differences
in Type of Small Protein may further Elucidate
Lung Cancer Risk
in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate
Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the
Lung Cancer Ribbon?
Management of chemotherapy - related anaemia with low - dose recombinant human erythropoietin
in patients with small
cell lung cancer.
Long - term survival
in patients with non-small
cell lung cancer and synchronous brain metastasis treated with whole - brain radiotherapy and thoracic chemoradiation.
One of the major parameters was the safety of these agents
in the respiratory airways and
lung parenchyma, since several of these agents are known to cause adverse effects.23 The main adverse effects observed were cough, transient fever and transient decrease
in the respiratory functions after the aerosol administration.8, 19, 20 Moreover; it has been observed that excessive deposition of these agents
in one site of the respiratory system can induce non-specific side effects
in the form of pulmonary edema as observed with many other drugs.16 These side effects were milder when a premedication with bronchodilators and inhaled corticosteroids were administered.8, 19, 20 Until now no long term trial (> 9 months) has been performed since all
patients included
in previous studies had stage IV non-small
cell lung cancer (NSCLC).
Short Research Communication The Factors Reducing Relative Dose Intensity of Cisplatin and Vinorelbine as Adjuvant Chemotherapy
in Patients with Non-Small
Cell Lung Cancer Ryo Inose, Katsuyuki Takahashi, Naruo Yoshimura, Tomoya Kawaguchi, Mitsutaka Takada, Katsuya Nagayama Oncomedicine 2018; 3: 9 - 14.